AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights:
-
Graft Polymer (UK) PLC announces a research agreement between its partner, Awakn Life Sciences, and the University of Nottingham to study a new chemical compound aimed at improving social cognition and pro-social behaviors.
-
The research, led by Dr. Madeleine King, will utilize rodent models to assess the therapeutic potential of the co-developed compound in treating mental health conditions like post-traumatic stress disorder (PTSD).
-
This initiative is part of Graft Polymer's ongoing commitment to develop innovative therapies for mental health, addressing critical needs in trauma-related disorders.
Graft Polymer (UK) PLC (LSE:GPL) has announced that its partner, Awakn Life Sciences, has entered into a research agreement with the University of Nottingham. This collaborative study will investigate a new chemical compound co-developed by both companies, focusing on its potential to enhance social cognition and pro-social behaviors, which are crucial in the treatment of mental health conditions such as post-traumatic stress disorder (PTSD).
The research will be led by Dr. Madeleine King, a recognized expert in behavioral neuroscience. The study aims to evaluate the compound's efficacy using rodent models through a method known as the social transmission of food preferences. This approach will help assess how the compound influences social behaviors, providing valuable insights into its therapeutic potential.
Anticipated to conclude by the end of 2024, this study represents a significant milestone in the pursuit of new treatments for trauma-related disorders. The initiative aligns with Graft Polymer's mission to develop innovative therapies that address pressing mental health issues affecting millions of individuals worldwide.
Graft's CEO, Anthony Tennyson, highlighted the importance of this collaboration, stating, "This is a significant step forward in our joint programme with Awakn. The in vivo testing at the University of Nottingham will be pivotal in assessing the therapeutic potential of our novel aminoindane compounds, bringing us closer to addressing the unmet needs in trauma-related mental health disorders."
By advancing research in this area, Graft Polymer and Awakn Life Sciences aim to contribute to the development of effective treatments that can significantly improve the quality of life for individuals suffering from trauma-related mental health conditions. This partnership underscores the commitment of both organizations to push the boundaries of mental health therapy through scientific innovation and collaboration.
